Automobiles
Bristol Myers Squibb Enters In Vivo CAR-T Field with $1.5B Acquisition of Orbital Therapeutics
Bristol Myers Squibb; Orbital Therapeutics; in vivo CAR T-cell therapy; autoimmune diseases; RNA medicines; OTX-201; cell therapy; acquisition; LNP delivery; circular RNA; immune system reprogramming
Galapagos Walks Back Split Plans, Raising Questions Over Cell Therapy Assets
Galapagos; company split; cell therapy; spinoff; CEO appointment; biotech industry; CAR T business
BMS’ CAR-T Therapy Shows Promising Results in Treating Lupus, Achieving Sustained Responses in Phase 1 Trial
CAR T therapy, Lupus treatment, Bristol Myers Squibb (BMS), Systemic lupus erythematosus (SLE), Autoimmune diseases, Cell therapy, Clinical trials
Nkarta Shifts Focus to Autoimmune Diseases, Deprioritizing Cancer Programs
Nkarta, autoimmune diseases, CAR NK cell therapy, NKX019, lupus nephritis, cancer programs, deprioritization
Gilead and Arcellx Highlight Promising CAR T Therapy for Multiple Myeloma with Enhanced Safety Profile
CAR T therapy, multiple myeloma, anito-cel, Gilead, Arcellx, safety profile, efficacy, clinical trials
FDA Mandates Enhanced Safety Warnings for CAR-T Therapies Due to Secondary Cancer Risks
CAR-T therapy, secondary cancers, FDA boxed warnings, T-cell malignancies, BCMA-directed, CD19-directed, autologous CAR T-cell immunotherapies.
Lyell Immunopharma Acquires ImmPACT Bio to Bolster CAR T-cell Therapy Pipeline
Lyell Immunopharma, ImmPACT Bio, CAR T-cell therapy, pipeline acquisition, biotechnology, cancer treatment, autoimmune diseases
Breakthrough in Lupus Treatment: CAR T-Cell Therapy Shows Promising Results
CAR T-cell therapy, lupus, autoimmune disease, cancer treatment, immunology